Recommended NZ | Guide to Money | Gimme: Competitions - Giveaways

BTX 1204 atopic dermatitis study results presentation

Fuseworks Media
Fuseworks Media

Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, "Botanix" or "The Company") is pleased to release a presentation containing supplementary information on the BTX 1204 atopic dermatitis Phase 1b study results.

Key highlights

- Study data indicated BTX 1204 was twice as effective over the vehicle with substantial improvement in the key signs of atopic dermatitis

- BTX 1204’s efficacy still increasing at the 4-week timepoint, suggesting a longer treatment period enables BTX 1204 to potentially exceed industry performance

- Achieved clear separation from vehicle, with BTX 1204 showing superiority over vehicle at an early stage of the treatment period

- BTX 1204 demonstrated an excellent safety profile allowing for extended dosing, which remains a key challenge for other available therapies

Botanix Executive Director Matt Callahan said: "We are extremely pleased with the results of our BTX 1204 atopic dermatitis study after a relatively short treatment period of just 4-weeks. There is potential for BTX 1204 to exceed the performance of other products over a longer treatment period, given efficacy was still increasing at the end of the treatment period along with the excellent safety profile demonstrated by BTX 1204. Further, the substantial reduction in key signs of atopic dermatitis, provides us with the confidence that the unmet needs of itch and underlying inflammation can be addressed."

All articles and comments on have been submitted by our community of users. Please notify us if you believe an item on this site breaches our community guidelines.